Navigation Links
Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Date:10/27/2009

o-inflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Rilonacept has not been studied in patients with NOMID.

CAPS are characterized by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can be triggered at any time by exposure to cooling temperatures, stress, exercise, or other unknown stimuli.

CAPS are generally caused by autosomal-dominant mutations (changes) in the NLRP-3 (previously known as CIAS1) gene and resultant alterations in the protein, cryopyrin, which it encodes. Cryopyrin, active in circulating, infection-fighting, white blood cells, controls the production of a protein called interleukin-1 (IL-1). As part of the body's infection-fighting defense system, IL-1 circulates throughout the body and can trigger inflammatory reactions when it binds to inflammatory cells. Researchers have found that alterations in the cryopyrin protein lead to over-production of IL-1, resulting in an inflammatory response and the symptoms of CAPS. Most, but not all, patients with CAPS have the NLRP-3 gene mutation.

The incidence of CAPS has been estimated to be approximately 1 in 1,000,000 people in the European Union.

About Rilonacept

Rilonacept is a targeted inhibitor of interleukin-1 (IL-1), the key driver of inflammation in Cryopyrin-Associated Periodic Syndromes (CAPS). In the pivotal clinical development program for rilonacept, change in disease activity was measured using a composite patient-reported symptom score composed of a daily evaluation of rash, feelings of fever/chills, joint pain, eye redness/pain, and fatigue. Patients treated with rilonacept experienced an improvement in overall symptom scores as compared with patients treated with placebo. These improvements were sustained over time with continued treatment with rilonacept.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Celsis IVT Granted U.S. Patent for LiverPool(TM) Hepatocytes
2. Peripheral Artery Disease (PAD) Patent Granted to Dimera
3. Sundia and 2 Other CRO Companies Granted Express Customs Clearance Privilege in Shanghai
4. Delcath Systems Granted Third Orphan Drug Designation
5. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
8. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
9. VIASPACE Granted US Patent
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... development of novel therapies for cancer, announced today that ... will present at BioCentury,s NewsMakers in the Biotech Industry ... Eastern time from the Millennium Broadway Hotel & Conference Center ... of the presentation can be accessed at www.meipharma.com . ...
(Date:9/18/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... underwritten offerings of 10,000,000 shares of its Common Stock ... share, for expected gross proceeds of $20 million and ... at a price to the public of $2,000.00 per ... share of Series A Convertible Preferred Stock is non-voting ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014   ... announced today it has entered into a new ... (U-M) Medical School,s Vector Core. Under the partnership, ... CRISPR technology, experimental design consultation, and dedicated gene ... to accelerate gene editing-based research at the U-M ...
(Date:9/18/2014)... September 18, 2014 SeqLL Inc., ... (tSMS™) technology, announced today the closing of a ... led by Genomic Diagnostic Technologies, will increase the ... applications. , Founded in March 2013 by Daniel ... Analyst at Helicos BioSciences, SeqLL has continued to ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... Andreas Krebs Named President of Europe/Middle East/Africa and ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... to President - Europe/Middle East/Africa,and Canada, effective immediately. ... Joseph M. Mahady, President - Wyeth Pharmaceuticals, and ...
... Sciences, LLC, a,member company of W. R. Berkley ... Prime is a uniquely innovative primary,liability policy designed ... companies of all sizes., LS Prime features ... and premises operations coverages. Included,with this broad protection ...
... Collagen ... Properties of Radiesse, SAN MATEO, Calif., June 26 ... of five studies in the,June 2008 issue of the Journal ... Dermatologic Surgery. The five,published clinical and preclinical reports were:, ...
Cached Biology Technology:Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry 2Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 2Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 3Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 4Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 5Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers 6
(Date:9/19/2014)... study shows that legume plants regulate their symbiotic ... that are transmitted through the plant structure from ... of bacteria-holding nodules in the roots. This collaborative ... Institute for Basic Biology, the Graduate University for ... Sustainable Resource Science in Japan. , Legumes, ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
(Date:9/18/2014)... Colo., USA Miranda, a small, icy moon of ... enigmatic bodies in the solar system. Despite its relatively ... of intense resurfacing that resulted in the formation of ... polygonal-shaped regions called coronae. , These coronae are ... at least 200 km across. Arden corona, the largest, ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7
... problem with today,s solar panels; they only collect about ... Missouri engineer has developed a flexible solar sheet that ... he plans to make prototypes available to consumers within ... professor in the MU Chemical Engineering Department, says energy ...
... University,s Courant Institute of Mathematical Sciences have outlined a ... at the molecular level. Co-authored by Jessie Chang and ... Framework for Nanocomputing (Morgan and Claypool) describes how to ... be peeled away one at a time from each ...
... identified a lung protein that appears to play a ... antibody to block its activity, Indiana University scientists reported. ... protein, a cytokine named EMAPII, could provide a target ... associate professor of medicine at the Indiana University School ...
Cached Biology News:New solar product captures up to 95 percent of light energy 2NYU researchers outline method for DNA computation in new book 2Protein could offer target to reduce lung damage from smoking-caused emphysema 2
Anti-rat Dipeptidyl Peptidase IV (DPP IV), CD26, Clone 5E8, Monoclonal Antibody...
... Immunogen: KLH-conjugated, synthetic ... in which [ Ac K] corresponds to ... Accession Number: NM_003493 ... ~17kDa Quality Assurance: ...
Anti-Mouse Ly 6C.2 , Ascites (Clone 5075-3.6) (mouse IgG2b)...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
Biology Products: